JP2010174030A5 - - Google Patents

Download PDF

Info

Publication number
JP2010174030A5
JP2010174030A5 JP2010074109A JP2010074109A JP2010174030A5 JP 2010174030 A5 JP2010174030 A5 JP 2010174030A5 JP 2010074109 A JP2010074109 A JP 2010074109A JP 2010074109 A JP2010074109 A JP 2010074109A JP 2010174030 A5 JP2010174030 A5 JP 2010174030A5
Authority
JP
Japan
Prior art keywords
antibacterial agent
antibiotic
clarithromycin
tetracycline
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010074109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010174030A (ja
JP5335726B2 (ja
Filing date
Publication date
Priority claimed from AUPP4376A external-priority patent/AUPP437698A0/en
Application filed filed Critical
Publication of JP2010174030A publication Critical patent/JP2010174030A/ja
Publication of JP2010174030A5 publication Critical patent/JP2010174030A5/ja
Application granted granted Critical
Publication of JP5335726B2 publication Critical patent/JP5335726B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2010074109A 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物 Expired - Lifetime JP5335726B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP4376 1998-06-30
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000557825A Division JP4651816B2 (ja) 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013076511A Division JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2010174030A JP2010174030A (ja) 2010-08-12
JP2010174030A5 true JP2010174030A5 (cg-RX-API-DMAC7.html) 2011-06-16
JP5335726B2 JP5335726B2 (ja) 2013-11-06

Family

ID=3808619

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000557825A Expired - Lifetime JP4651816B2 (ja) 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2010074109A Expired - Lifetime JP5335726B2 (ja) 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2013076511A Pending JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000557825A Expired - Lifetime JP4651816B2 (ja) 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013076511A Pending JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Country Status (10)

Country Link
US (1) US6475518B1 (cg-RX-API-DMAC7.html)
EP (2) EP1754472B1 (cg-RX-API-DMAC7.html)
JP (3) JP4651816B2 (cg-RX-API-DMAC7.html)
AT (1) ATE345115T1 (cg-RX-API-DMAC7.html)
AU (2) AUPP437698A0 (cg-RX-API-DMAC7.html)
CA (2) CA2684402C (cg-RX-API-DMAC7.html)
DE (1) DE69934010T2 (cg-RX-API-DMAC7.html)
ES (2) ES2278449T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ509504A (cg-RX-API-DMAC7.html)
WO (1) WO2000001378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
EP1267765A4 (en) * 2000-02-24 2008-12-24 Middlebrook Pharmaceuticals In ANTIBIOTIC AND MUSHROOM AGENTS
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
YU69802A (sh) * 2000-03-22 2005-11-28 Pharmacia & Upjohn Company Formulacija oksazolidinon tablete
IT1318459B1 (it) * 2000-04-11 2003-08-25 Zambon Spa Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (en) * 2001-05-30 2002-12-04 New Pharma Research Sweden AB Synergistic antibiotic compositions
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
WO2003099217A2 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US20040176404A1 (en) * 2002-12-12 2004-09-09 Sayada Chalom B. Methods and reagents for treating or preventing atherosclerosis and diseases associated therewith
US20040126414A1 (en) * 2002-12-12 2004-07-01 Michaelis Arthur F. Methods and compositions for treating and preventing ear infections
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) * 2003-08-11 2005-06-20 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
WO2005074908A1 (en) 2004-02-06 2005-08-18 Borody, Thomas, Julius Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
EA016776B9 (ru) 2004-09-30 2012-11-30 Ковалон Текнолоджиз Инк. Неадгезивные эластичные желатиновые матрицы
JPWO2006057429A1 (ja) * 2004-11-24 2008-06-05 ナノキャリア株式会社 ブロックコポリマーのモーフォロジーの変化方法
CA2620091A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
WO2009015214A2 (en) * 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
US8999360B2 (en) * 2009-10-22 2015-04-07 Thomas Julius Borody Compositions and methods for treating extracellular parasitic infections
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2011137103A1 (en) 2010-04-26 2011-11-03 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
CA2843696C (en) * 2011-08-16 2019-09-24 Purac Biochem B.V. Recovery of carboxylic acid from their magnesium salts by precipitation using hydrochloric acid, useful for fermentation broth work-up
ES2717282T3 (es) 2012-07-27 2019-06-20 Redhill Biopharma Ltd Formulaciones y métodos para fabricar formulaciones para su uso en la evacuación colónica
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
KR20180058716A (ko) * 2015-10-06 2018-06-01 레드힐 바이오파마 엘티디 암을 치료하기 위한 병용 요법
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン:癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US11667639B2 (en) 2017-06-26 2023-06-06 Lunella Biotech, Inc. Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
WO2019148249A1 (en) * 2018-02-01 2019-08-08 Centre For Digestive Diseases Compositions for treating infective arterial diseases and related conditions
RU2684728C1 (ru) * 2018-05-21 2019-04-12 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
CA3180390A1 (en) * 2020-03-27 2021-09-30 Fergus MANFORD Compositions for the treatment of a respiratory condition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588550A (en) 1897-08-24 Alarm-clock
GB1463550A (en) 1974-08-06 1977-02-02 Bodrero G Pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI883067A7 (fi) * 1988-06-27 1989-12-28 Labsystems Oy Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) * 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

Similar Documents

Publication Publication Date Title
JP2010174030A5 (cg-RX-API-DMAC7.html)
IL211120A (en) Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
JP2010285439A5 (cg-RX-API-DMAC7.html)
BRPI0821855A2 (pt) Composto, agente farmacêutico, uso de um composto inibidor de dna girase bacteriana, agente antibacteriano, e, agente terapêutico para doença infecciosa
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
WO2008116813A3 (en) Combination medicaments for treating bacterial infections
HK1205939A1 (en) Parenteral formulations for administering macrolide antibiotics
IL218277B (en) Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection
WO2008067982A3 (en) Use of carrageenan for treating rhinovirus infections
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
IL187904A (en) Use of quinoline derivatives for the preparation of bacterial preparations for the treatment of bacteria caused by bacteria
JP2007510757A5 (cg-RX-API-DMAC7.html)
BRPI0816236A2 (pt) Peptídeo cdh3 e agente medicinal contendo o mesmo
JP2015532923A5 (cg-RX-API-DMAC7.html)
JP2009539970A5 (cg-RX-API-DMAC7.html)
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
JP2018500387A5 (cg-RX-API-DMAC7.html)
IN2014CN02908A (cg-RX-API-DMAC7.html)
WO2007116102A3 (en) Therapeutic composition and use
IL197783A (en) Polycyclic compounds, preparations containing them and polycyclic compounds for use in the treatment of synthetic respiratory virus infections
WO2008097364A3 (en) Use of oritavancin for prevention and treatment of anthrax
IL210975A (en) Annapomapungin History, Pharmaceuticals Containing Them and Their Use in Preparing Medicines to Treat Fungal Infections
JP2010525044A5 (cg-RX-API-DMAC7.html)
TW200602090A (en) Antibiotic-based pharmaceutical formulation in microcapsular form